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SUMMARY
Emergencies in dermatology are well recognized
and are associated with significant morbidity and
mortality.  Early recognition of these conditions
with institution of prompt   medical care can help
in reducing the morbidity and mortality
associated with these conditions. This article
reviews relevant dermatologic emergencies with
respect to this environment with emphasis on
current trends in management. Prompt and
aggressive management of  dermatologic
emergencies are important to reduce mortality
related to these skin disorders so as to prevent
skin failure. Dermatologic emergencies are
clinical conditions which lead to increased
morbidity and mortality. Recognizing them and
the urgency required in their management would
help in reducing the attendant skin failure that
may arise from these conditions.
Keywords: Dermatologic emergency, skin
failure, management.
INTRODUCTION
Dermatologic emergencies are a well recognized
group of disorders requiring prompt treatment. They
could all lead to acute skin failure with its attendant
sequelae such as sepsis, multi organ failure and
pulmonary embolism.
Skin failure is an emerging concept which
refers to a state of total dysfunction of the skin
resulting from different aetiological factors [1, 2].
There is loss of normal temperature control with
inability to maintain the core body temperature. There
is also percutaneous fluid, electrolyte and protein
loss resulting in various complications. The barrier
mechanism against foreign materials is also
compromised [1, 2].
Dermatologic emergencies to be discussed
include the following:
1. Stevens Johnson syndrome –Toxic epidermal
necrolysis
2. Pemphigus vulgaris
3. Staphylococcal scalded skin syndrome
4. Lepra reaction
5. Angioedema
The effective management of each of the
above listed conditions is possible only when the
underlying pathogenic mechanism is clear to the
treating clinician.
TOXIC EPIDERMAL NECROLYSIS AND
STEVENS JOHNSON’S SYNDROME
Both Steven Johnson’s syndrome (SJS) and Toxic
Epidermal Necrolysis (TEN)  are blistering
conditions of the skin which may result in high
morbidity and mortality. It is believed that they both
represent different spectra of the same disease.
However, some feel they are different disease entities.
TEN was first described by Alan Lyell in 1956 [3,
4]. TEN is the most severe form of cutaneous drug
reaction. It is a rapidly evolving mucocutaneous
reaction characterized by widespread erythema,
necrosis and bullous detachment of extensive areas
of the epidermis. Steven Johnson’s would be
described as erythema multiforme with more than
one mucous membrane involvement. TEN
represents the most severe variant of a disease
spectrum that includes bullous erythema multiforme
and Stevens Johnson syndrome.
The differentiation between toxic epidermal
necrolysis and Stevens Johnson syndrome is mainly
clinical. In TEN, the disease is more severe with
epidermal detachment greater than 30% [5, 6] while
in Stevens  Johnson syndrome, epidermal
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detachment is less that 10% of body surface area.
The patient in Stevens-Johnson’s syndrome also has
target lesions [5, 6].
Aetio-Pathogenesis
The causes of the two conditions are numerous.
Drugs are the major precipitating cause of TEN and
SJS. Viral infections have also been implicated in
the aetiology of these two conditions, especially in
patients who have recurrent SJS in the absence of
drug use. Common drugs implicated include
sulphonamides, quinolones, anticonvulsants like
phenobarbitone, phenytion and carbamazepine.
Listed as a possible cause but very rarely seen in
our environment is erythromycin [21, 22].
Most likely mechanism favoured is an immune
complex reaction. One theory suggests that
accumulation of drug metabolites in the epidermis in
genetically predisposed individuals induces an
immunologic process analogous to that which occurs
in graft versus host disease. CD8
+ T lymphocytes
and macrophages activate an inflammatory cascade,
leading to widespread apoptosis of epidermal cells.
Clinical Features
Patients with TEN and SJS are usually ill and may
present with pyrexia [6, 7, 8, 9]. Examination of the
skin may show generalized papular exanthem,
purpuric macules, atypical target lesions, bullae or
erosions.
Skin lesions rapidly coalesce in patients with
TEN producing large blisters. The lesions separate
with light pressure (Nikolsky sign) in patients with
TEN and the underlying denuded skin is
erythematous [5, 6, 7]. Involvement of mucosa, oral,
ocular, genital and respiratory systems vary in the
two conditions and this leads to variation in
complications seen.
Mucosal membrane involvement and “target
lesions” erythema multiforme are more common in
Stevens-Johnson’s syndrome. The most frequently
affected membrane is the oropharynx followed by
the eyes and genitals.
Skin biopsy may be indicated in some cases
where the diagnosis is in doubt.  Full thickness
epidermal necrosis is seen in TEN while satellite cell
necrosis may be seen in SJS. Other useful
investigations include complete blood count,
urinalysis, serum electrolyte and urea estimation and
activated partial prothrombin time. The liver function
test may also be included in some patients.
Management
Early recognition and prompt withdrawal of the
causative agent and referral to a burns unit improves
outcome.
- Aggressive fluid and electrolyte management
is essential. Patients with respiratory involv-
ement should be monitored carefully to
prevent pulmonary oedema. Marked vaso-
dilation of blood vessels  may lead to high out
put failure in the elderly.
- Respiratory distress may result from mucosal
sloughing and may necessitate endotracheal
intubation.
- Meticulous skin care is mandatory. Areas of
skin erosion in TEN should be covered with
non-adherent protective dressing such as
petroleum gauze, preferably sterile.
- Silver sulphadiazine should be avoided bec-
ause it is a sulphonamide derivative and may
precipitate TEN.
Drug use is minimized as cross reactions to
other drugs could also worsen the skin reaction.
Although it is said that antibiotics are useful only when
sepsis is strongly considered, it is advisable to use
antibiotics routinely in patients in  this environment
as there is usually some bacterial infection of the skin.
The use of steroids in this group of patients remains
controversial. Theoretically steroids inhibit further
immune complex reactions in the skin, however
immune suppression from the steroids reduce the
ability of the patient to fight infection. However,
steroids may be beneficial to the patient if new lesions
continue to develop. The use of  intravenous
immunoglobulin G (IVIG) in these patients remains
controversial. Some reports  demonstrate favourable
outcome. Immediate discontinuation of offending
drugs should be emphasized.
Other specialist such as the ophthalmologists,
plastic surgeons, respiratory physicians and
gastroenterologists should be involved in the
management of patients when indicated.
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Complications
Sepsis, pain and scarring of mucosal membranes
occur in many cases. Dry eyes, entropion , vulvo-
vaginal synechiae and phimosis have been reported.
Gastrointestinal haemorrhage  may result from
intestinal inflammation. Acute renal insufficiency
results from poor intake and septic shock which may
induce renal hypoperfusion.
Prognosis in TEN is poor with mortality rates as
high as 40%.
PEMPHIGUS VULGARIS
Pemphigus vulgaris (PV) is an autoimmune disorder
characterized by  generalized intraepidermal
blistering of the skin  accentuated initially in
intertriginous regions [10, 11].
Pathogenesis
Pemphigus vulgaris results from autoimmunity to the
pemphigus vulgaris antigen [12]. In addition lower
molecular weight species have been extracted form
human and other vertebrate epithelial tissues which
are also identified by circulating autoantibodies from
patients with this disease [13]. Pemphigus vulgaris
has been reproduced at histologic, immunologic and
clinical levels when pemphigus vulgaris IgG was
infused intraperitoneally into new born mice [14]. It
is believed that acantholysis is the end result of
plasmin induced proteolysis which results from
binding of pemphigus autoantibody to pemphigus
antigen on keratinocyte cell membranes, production
and release of plasminogen activator and subsequent
conversion of plasminogen to plasmin within the
affected epidermis.
Clinical Features
Patients with PV are usually quite ill. Fever, chills,
rigours, and head ache are not uncommon. Mucous
membrane involvement is also common manifesting
with sore throat, dysphagia, dysuria and vaginal pain.
When large areas of the skin gets denuded from
ruptured blisters  there may be marked fluid and
protein losses leading to severe electrolyte
imbalance, hypoalbuminemia and development of
life-threatening secondary bacterial infections.
Management
Pemphigus vulgaris may be rapidly fatal without
treatment. Large doses of corticosteroids are usually
required. Oral daily doses of corticosteroids may
range between 120-150mg of prednisolone or 1 gm
of methyl prednisolone daily in the first 3-5 days.
Most patients are treated with corticosteroids and a
steroid sparing immunosuppressant e.g. azathioprine
or cyclosphosphamide. Plasmapheresis has been
used in conjunction with immunosuppressant therapy
to prevent autoantibody rebound. This may be in
addition to intravenous pulse therapy with high dose
steroids [15].  Results of various therapies vary [16].
Antibiotics are also required to prevent
overwhelming infections. Fluid and electrolyte
balance should also be managed carefully. It is also
important to remember that certain drugs could




This condition is commonly seen in infants and
children. It is caused by Staphyloccus aureus phage
type 71 due to liberation of exotoxin [17].
The clinical features include diffuse erythema,
fever, tender skin, large flaccid bullae with clear fluid
which rupture soon after being formed. This may
lead to extensive loss of the skin surface. Lesions
usually start in the head and migrate downwards
[18]. In Staphylococcal scaled skin syndrome, the
exfoliative toxins are spread haematogenously from
a localized source causing widespread epidermal
damage at distant sites [17].  Patients should be
admitted preferably in a burns unit. The lesions should
be managed like those other conditions listed above.
Fluid and electrolyte balance must be monitored and
appropriate antibiotics should be used. It is
associated with high mortality
LEPRA REACTIONS
Lepra reactions occur in the course of leprosy. They
are sudden exacerbations in the clinical state  of a
patient with pauci or multibacillary leprosy[19].
These reactions are treated as emergencies as they
may lead to irreversible damage to nerves leading
to loss of functions of limbs or blindness. Sometimes
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lepra reactions are due to immunological changes
following effective treatment and reduction in bacillary
load [19]. Other factors that may provoke leprae
reactions  include intercurrent infections with  malaria
or viruses. Lepra reactions are of two types.
Type 1 reaction
This is an example of type IV hypersensitivity
reaction. It involves cell mediated immunity and is
seen in the entire spectrum of leprosy except
lepromatous type [19]. It manifests as a local
aggravation of an existing lesion which become more
erythematous and indurated with increased loss of
sensation. The lesions may be painful with
paraesthesis. The nerve may become extremely
painful and tender. When it is due to increase in cell
mediated immunity, the term reversal or upgrading
is used. It occurs during treatment. When it is
associated with decrease in cell mediated iummunity,
the word “downgrading” is used. Downgrading
reactions occur in a patient not on treatment.
Type II reaction
This reaction is also known as erythema nodosum
leprosum (ENL). It is mediated by humoral
hypersensitivity.  Usually occurs later during the
course of treatment for lepromatous and borderline
lepromatous leprosy. Type II reaction manifests as
recurrent, tender erythematous nodules, appearing
suddenly on any part of the body. Other features
like joint pain, fever, malaise may be present [19].
Treatment
Type 1 reactions should be treated with systemic
corticosteroids especially when there is nerve
involvement. Non steroidal anti inflammatory drugs
are also useful.
 Type II reactions require the use of oral
steroids or clofazimine. Thalidomide in a dose of
100mg to 400mg daily has also been found to be
effective.
ANGIOEDEMA
Urticaria and angioedema are common cutaneous
vascular reaction patterns. Urticaria is characterised
by transient, pruritic edematous, lightly erythematous
papules or wheals frequently with central clearing
which may vary in size from a few to many
centimetres in diameter. The individual lesions are
transient lasting 12 to 24hours or less [19].
Angioedema is the term used to describe a
process that is in most respect similar to urticaria
but involves deeper subcutaneous structures [19].
Both conditions may occur in the same individual.
Life threatening reactions are associated with
angioedema especially when the respiratory mucous
membranes are involved leading to laryngeal oedema.
Severe attacks may be associated with abdominal
pain, nausea, vomiting due to intestinal obstruction
in children. Headaches and high fever may also
occur  in children. These are all mediated by
histamine. Most cases are Type 1 hypersensitivity
reactions which are mediated by IgE antibodies fixed
on the surface of  tissue mast cells and basophils.
As a result of antigen-antibody reaction on mast cells,
degranulation of mast cells occur leading to the
release of histamine which causes itching,
vasodilatation, and increased permeability of blood
vessels resulting in the formation of wheals.
Sometimes urticaria is due to Type III hypersensitivity
reaction and is mediated by IgG antibodies which
form immune complexes with antigens leading to
release of vasoactive substances from complement
components which release histamine with the
formation of wheals. A Type III mechanism is
implicated in urticarial vasculitis.
Factors implicated in urticaria include
anaphylatoxins (C3a and C5a), kinins, serotonin,
prostaglandins, fibrin degradation products, and
substance P [20]. Genetic factors are implicated in
some rare types of urticaria and angioedema.
Hereditary angioedema, familial cold urticaria,
vibratory angioedema, and Muckle-Wells syndrome
(a heredo-familial syndrome of urticaria, deafness
and amyloidosis). The role of C1 esterase  inhibitor
deficiency in hereditary angioedema is one of the
best examples. Some patients with cold intolerance
have been found to have reduced alpha-1antirypsin
and chemotrypsin activity[21]. Patients on
angiotensin converting enzyme inhibitors may also
develop angioedema.
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Toxic epidermal Necrolysis
Stevens-Johnson Syndrome in a child Stevens-Johnson Syndrome with target lesions
Management
Angioedema of the glaborous skin is usually not
dangerous. However involvement of the mucous
membrane may be dangerous. Such patients may
present with complains of lumps in their throats or
difficulty with breathing. Such patients   should be
observed carefully.
Parenteral Corticosteroids or epinephrine may
be used in severe attacks. Danazol has also been
found to be very useful. If due to ACE inhibitors,
this must be stopped.
Traditional anti-histamines of the H1 type are
useful in prophylactic management. Side effects
should be looked out for. Newer antihistamines with
non-sedating effects are preferred. Non-sedating H1
anti-histamines e.g. terfenadine, astemizole and
loratadine.
Some tricyclic antidepressants have been
found useful in chronic urticaria because they exert
potent H1 antihistamine effects [22].
Detailed history is very important. Suspected
urticaria due to a food item can be confirmed by
disappearance of the urticaria within 48hrs after
stoppage of the particular food (diet elimination test)
or by giving a certain food with recurrence of the
urticaria (provocation test).
CONCLUSION
Dermatologic emergencies are important clinical
conditions, which contribute significantly to morbidity
and mortality in health care delivery. Although various
pathophysiologic mechanisms are involved in the
occurrence of these lesions they may ultimately lead
to skin failure and consequently complications of the
skin. Dermatologic emergencies should therefore be
earlier identified as such and should be given the
urgency required in management to prevent
avoidable mortality which arises from a number of
these conditions where possible.
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